MannKind Corp.

MannKind Corp.

MannKind Corp.

Overview
Date Founded

1991

Headquarters

30930 Russell Ranch Road,Suite 301,Westlake Village, CA 91362

Type of Company

Public

Employees (Worldwide)

233

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® (pronounced uh-FREZZ-uh) is a novel, ultra rapid-acting mealtime insulin therapy. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. It is a drug-device combination product, consisting of AFREZZA inhalation powder pre-metered into single use dose cartridges and the light, discreet and easy-to-use AFREZZA inhaler. Because of its unique pharmacokinetic profile, AFREZZA may be a promising new therapy for patients with Type 1 and Type 2 diabetes, as it controls post meal-time glucose levels with less weight gain and lower risk of hypoglycemia. AFREZZA utilizes our proprietary Technosphere® formulation technology, which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Beyond convenience, we believe the key advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation

Contact Data
Trying to get in touch with decision makers at MannKind Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & Director

Chief Financial Officer & Principal Accounting Officer

Corporate Vice President, General Counsel & Corporate Secretary

Chief Technology Officer

Chief Commercial Officer

Vice President, Chief Compliance & Privacy Officer

Chief People & Workplace Officer

Chief Medical Officer

Controller

Senior Vice President, Human Resources

Board of Directors

Vice Chairman at The Music Center

Former Head of Global Business Development at iShares, Inc.

Managing Director at Synergy Trading LLC

Former President of International Medicines, Asia-Pacific, Middle East & Southern Africa at Bristol-Myers Squibb Company

Director & Chief Executive Officer at MannKind Corp.

Former President & Chief Executive Officer at Sandoz, Inc.

Paths to MannKind Corp.
Potential Connections via
Relationship Science
You
MannKind Corp.
Owners & Shareholders
Details Hidden

Raging Capital Management predominately employs a long-short strategy on behalf of the funds, which focuses mainly on small- to mid-cap US companies. Each SPV generally holds a specific underlying investment, which may be held directly by the funds or used to facilitate a specific co-investment opportunity.Raging Capital seeks to achieve superior long-term, absolute, risk-adjusted returns regardless of overall market performance without taking outsized risks, and to maximize after tax returns. To achieve this, the firm employs a hedged/long-short, generalist investment strategy that invests primarily in equity and debt securities of small to mid-cap US companies, with primary focus on companies that are not well covered by Wall Street analysts. Raging Capital also selectively executes activist strategies, which may include advocating to change the board composition, corporate strategy and/or financial strategy of the funds' portfolio companies when they believe such actions will help protect and maximize the value of the funds' investments. Raging Capital uses a fundamental and research-driven in which returns are derived from security selection, not market direction. In managing the funds, Raging Capital may use complementary derivatives in order to selectively enhance returns and/or reduce risk.Raging Capital Management is an activist firm and is included in the SharkWatch50 as one the 50 most prominent activist investors.

Details Hidden

Part of Parkman Healthcare Partners Holdings LP, Parkman Healthcare Partners LLC is a company headquartered in Stamford, CT. The firm provides investment advice. It was founded in 2018.

Details Hidden

Part of Parkman Healthcare Partners Holdings LP, Parkman Healthcare Partners LLC is a company headquartered in Stamford, CT. The firm provides investment advice. It was founded in 2018.

Recent Transactions
Details Hidden

MannKind Corp. raised money in a private placement transaction

Details Hidden

MannKind Corp. issued USD Common Stock

Details Hidden

MannKind Corp. issued USD Units

Transaction Advisors
Auditor

Advised onMannKind Corp. issued USD Common Stock

Underwriter

Advised onMannKind Corp. issued USD Common Stock

Underwriter

Advised onMannKind Corp. issued USD Common Stock

Legal Advisor

Advised onMannKind Corp. issued USD Common Stock

Managing Director

Advised onMannKind Corp. issued USD Common Stock

Head, Healthcare Investment Banking

Advised onMannKind Corp. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner, San Diego at Cooley LLP

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Legal Advisor

Partner at Cooley LLP

Clients

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

BIOMM SA engages in the research, development, and manufacture of insulin. Its technology is suitable for the production of therapeutic proteins such as calcitonin, interferons and growth hormones. The company was founded on September 19, 2001 and is headquartered in Belo Horizonte, Brazil.

Key Stats and Financials As of 2019
Market Capitalization
$260M
Total Enterprise Value
$331M
Earnings Per Share
$-0.27
Revenue
$63M
Net Profit
$-51.9M
TEVNet Income
-6.37x
Debt TEV
0.39x
Total Equity
$-191M
Total Debt
$129M
EBITDA
$-43.7M
Enterprise Value Sales
5.25x
EBITDAMargin
-69.37%
Three Year Compounded Annual Growth Rate Of Revenue
-28.81%
Non-Profit Donations & Grants
$25K - $100K
2016
$5,000 - $10K
2008
Suppliers
Amphastar Pharmaceuticals, Inc. Biotechnology | Rancho Cucamonga, California

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Competitors
Eli Lilly & Company Pharmaceuticals - Indianapolis, Indiana

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Novo Nordisk A/S Pharmaceuticals - Bagsværd, Denmark

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Sanofi Pharmaceuticals - Paris, France

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by MannKind Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of MannKind Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and MannKind Corp..